NeoGenomics Stock News

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

On relatively calm days, the tokens that jump often have exciting stories to tell.

NeoGenomics (NEO) unit Inivata reported positive data for its RaDaR liquid biopsy test in head and neck squamous cell carcinoma ((HNSCC)).In the LIONESS study, blood samples taken from

FT. MYERS, FL / ACCESSWIRE / February 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today anno

Neogenomics Inc. (NEO) shares closed 1.3% lower than its previous 52 week low, giving the company a market cap of $2B. The stock is currently down 37.3% year-to-date, down 61.0% over the past 12 months, and up 155.1% over the past five years. This week, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 4.1%. Trading Activity Trading volume this week was 3.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 400.4% The company's stock price performance over the past 12 months lags the peer average by -800.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 345.2% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

See two of the featured stocks from this month's model portfolios.

Neogenomics Inc. (NEO) shares closed today at 0.6% above its 52 week low of $24.85, giving the company a market cap of $3B. The stock is currently down 26.8% year-to-date, down 52.7% over the past 12 months, and up 190.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 28.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 453.2% The company's stock price performance over the past 12 months lags the peer average by -373.2% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 391.9% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Neogenomics Inc. (NEO) shares closed today at 0.8% above its 52 week low of $27.84, giving the company a market cap of $3B. The stock is currently down 17.8% year-to-date, down 47.6% over the past 12 months, and up 220.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 19.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 9.5% lower than its 5-day moving average, 14.0% lower than its 20-day moving average, and 31.7% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 415.7% The company's stock price performance over the past 12 months lags the peer average by -317.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 457.1% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Neogenomics Inc. (NEO) shares closed 1.9% lower than its previous 52 week low, giving the company a market cap of $3B. The stock is currently down 12.6% year-to-date, down 45.6% over the past 12 months, and up 235.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 8.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 391.5% The company's stock price performance over the past 12 months lags the peer average by -277.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 474.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Sector ETF report for PSCH

Catherine Faddis, Grace Capital founder and CEO, joins 'Closing Bell' to discuss her top healthcare stock picks.